🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "huge turning point" in the fight against drug-resistant strains of the infection, according to researchers.

An International Public Health Issue

Gonorrhoea infections are increasing around the world, with data suggesting over 82 million new cases annually. Especially elevated rates are seen in Africa and countries within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely step in the face of increasing worldwide cases, increasing antimicrobial resistance and the very limited available drugs at this time.”

Medical experts are deeply concerned about the surge in treatment-resistant strains. The WHO has listed it as a "critical concern". Ongoing monitoring showed that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Gain Clearance

Zoliflodacin, marketed under the name Nuzolvence, was approved by the American regulatory agency in recent days for treating gonorrhoea. This infection can lead to major issues, including infertility. Researchers anticipate that targeted use of this new drug will help delay the emergence of superbugs.

Gepotidacin, developed by the drugmaker GSK, gained clearance in the same week. This medication, which is employed against UTIs, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment stemmed from a unique collaborative effort for drug creation. The non-profit organisation GARDP collaborated with the drug firm its industry partner to bring it to fruition.

“This approval signifies a huge turning point in the treatment of highly resistant gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Research Study Data and Worldwide Availability

Based on results detailed in a major medical journal, zoliflodacin successfully treated the vast majority of cases of the STI. This establishes an equal footing with the existing first-line therapy, which uses a dual-drug approach. The trial included over 900 patients from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, GARDP has the rights to license and sell the drug in many low-income and middle-income countries.

Medical professionals directly involved have expressed hope. Having a one-pill regimen such as this is hailed as a "game-changer" for managing the epidemic. This is deemed vital to reduce the burden of the infection for patients and to prevent the spread of untreatable gonorrhoea around the world.